Shots:

• Ultimovacs has reported topline data from the P-II (FOCUS) study assessing the safety & efficacy of UV1 + Keytruda vs Keytruda alone (SoC) as a 1L treatment of metastatic patients or a 2L treatment of recurrent PD-L1 +ve HNSCC patients
• Topline data showed that UV1 with Keytruda did not show significant clinical advantages in the 1EPs & 2EPs of PFS at 6mos. and OS among patients with late-stage HNSCC
• The company is also conducting a P-II (DOVACC) study assessing olaparib & durvalumab +/- UV1 vs olaparib monotx. as 2L maintenance treatment of high-grade BRCA-ve ovarian cancer. Topline data is anticipated in H1’25